News
Biotech companies are using a new set of artificial intelligence products to hasten drug discovery and other scientific ...
StockStory.org on MSN2h
Why Regeneron (REGN) Shares Are Falling TodayShares of biotech company Regeneron (NASDAQ:REGN) fell 19% in the afternoon session after the company announced mixed results ...
4h
Zacks Investment Research on MSNGilead Sciences Stock Gains 21% YTD: Buy, Sell or Hold?Biotech giant Gilead Sciences, Inc. GILD has put up a strong performance amid a volatile market. Shares of this biotech giant ...
Take a closer look at London's biotech hub – renowned for its thriving life sciences ecosystem and world-class infrastructure ...
The company's flagship assay uses whole-genome sequencing to identify patients with high-risk multiple myeloma and determine which patients won't respond to therapies.
A US-based biotech company has successfully sequenced the genetic codes of preserved plants, some of which date back more ...
Castle Biosciences, Inc. (NASDAQ:CSTL)’s Dx-Melanoma test, which evaluates a 31-gene expression profile, offers significant, ...
Cytek Biosciences, Inc. (NASDAQ:CTKB) has announced the launch of its latest innovation, the Cytek Aurora Evo system, marking ...
Yes, PCRX’s Q1 was not pretty, miserable 1% sales growth rate and collapse of operating profit from last year’s Q1. But, hey, strategically, PCRX has the competition surrounded.
ZURICH, SWITZERLAND, May 29, 2025 -- VERAXA Biotech AG (“VERAXA”), an emerging leader in designing novel cancer therapies and proposed de-SPAC acquisition target of Voyager Acquisition Corp.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results